Vivoryon Total Other Income Expense Net from 2010 to 2026
| VVY Stock | 1.40 0.02 1.41% |
Total Other Income Expense Net | First Reported 2010-12-31 | Previous Quarter 143 K | Current Value 50 K | Quarterly Volatility 564 K |
Check Vivoryon Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vivoryon Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 127.7 K, Interest Expense of 59.2 K or Selling General Administrative of 8.3 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 7.18 or Book Value Per Share of 0.26. Vivoryon financial statements analysis is a perfect complement when working with Vivoryon Therapeutics Valuation or Volatility modules.
Vivoryon | Total Other Income Expense Net |
The evolution of Total Other Income Expense Net for Vivoryon Therapeutics NV provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Vivoryon Therapeutics compares to historical norms and industry peers.
Latest Vivoryon Therapeutics' Total Other Income Expense Net Growth Pattern
Below is the plot of the Total Other Income Expense Net of Vivoryon Therapeutics NV over the last few years. It is Vivoryon Therapeutics' Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vivoryon Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Other Income Expense Net | 10 Years Trend |
|
Total Other Income Expense Net |
| Timeline |
Vivoryon Total Other Income Expense Net Regression Statistics
| Arithmetic Mean | 160,666 | |
| Geometric Mean | 89,606 | |
| Coefficient Of Variation | 232.78 | |
| Mean Deviation | 313,157 | |
| Median | 8,000 | |
| Standard Deviation | 373,995 | |
| Sample Variance | 139.9B | |
| Range | 1.3M | |
| R-Value | 0.53 | |
| Mean Square Error | 106.7B | |
| R-Squared | 0.28 | |
| Significance | 0.03 | |
| Slope | 39,529 | |
| Total Sum of Squares | 2.2T |
Vivoryon Total Other Income Expense Net History
About Vivoryon Therapeutics Financial Statements
Vivoryon Therapeutics shareholders use historical fundamental indicators, such as Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Although Vivoryon Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Vivoryon Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Vivoryon Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Other Income Expense Net | 451.9 K | 474.5 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vivoryon Stock Analysis
When running Vivoryon Therapeutics' price analysis, check to measure Vivoryon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivoryon Therapeutics is operating at the current time. Most of Vivoryon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivoryon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivoryon Therapeutics' price. Additionally, you may evaluate how the addition of Vivoryon Therapeutics to your portfolios can decrease your overall portfolio volatility.